Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 1003 results for public health medicine & health

  1. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

  2. Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]

    Awaiting development Reference number: GID-TA11691 Expected publication date: TBC

  3. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  4. Care and support of people growing older with learning disabilities (NG96)

    This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

  5. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  6. About our guidance

    Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

  7. Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]

    Awaiting development Reference number: GID-TA11192 Expected publication date: TBC

  8. Eneboparatide for treating chronic hypoparathyroidism [TSID12145]

    Awaiting development Reference number: GID-TA11713 Expected publication date: TBC

  9. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

  10. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

  11. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

  12. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]

    Awaiting development Reference number: GID-TA11271 Expected publication date: TBC

  13. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

  14. Bimekizumab for treating ankylosing spondylitis [ID4011]

    Awaiting development Reference number: GID-TA11150 Expected publication date: TBC

  15. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC